Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents
Maria Antonietta Occhiuzzi, Gernando Lico, Giuseppina Ioele, et al.
European Journal of Medicinal Chemistry (2022) Vol. 246, pp. 114971-114971
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment
Fabio Raith, Daniel H. O’Donovan, Clara Lemos, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2289-2289
Open Access | Times Cited: 23
Inhibition of cancer cells by Quinoline-Based compounds: A review with mechanistic insights
Anjali Saxena, Suman Majee, Devalina Ray, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 103, pp. 117681-117681
Closed Access | Times Cited: 12
PI3Kδ and mTOR dual inhibitors: Design, synthesis and anticancer evaluation of 3-substituted aminomethylquinoline analogues
Digambar Yevale, Nishith Teraiya, Twinkle Lalwani, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107323-107323
Closed Access | Times Cited: 7
Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy
Mehlika Dilek Altıntop, İpek Ertorun, Gülşen Akalın Çiftçi, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116698-116698
Closed Access | Times Cited: 7
Strategies of nanomedicine for targeting the signaling pathways of Colorectal cancer
Mohammad Habeeb, Huay Woon You, Kiran Balasaheb Aher, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 84, pp. 104487-104487
Closed Access | Times Cited: 17
Anticancer activity of Ilex khasiana, a rare and endemic species of holly in Northeast India, against murine lymphoma
Charles Lalnunfela, Pawi Bawitlung Lalthanpuii, Hmar Tlawmte Lalremsanga, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41839-e41839
Open Access
Targeting PI3K in Cancer Treatment: A Comprehensive Review with Insights from Clinical Outcomes
Munier Hossain, Md. Arafat Hossain
European Journal of Pharmacology (2025), pp. 177432-177432
Closed Access
Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer
Mateusz Wylaź, A. Kaczmarská, Dawid Pajor, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115676-115676
Open Access | Times Cited: 14
Optimization of virtual screening against phosphoinositide 3-kinase delta: Integration of common feature pharmacophore and multicomplex-based molecular docking
Jingyu Zhu, Huiqin Meng, Xintong Li, et al.
Computational Biology and Chemistry (2024) Vol. 109, pp. 108011-108011
Closed Access | Times Cited: 4
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)
Dima A. Sabbah, Rima Hajjo, Sanaa K. Bardaweel, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 3, pp. 141-158
Closed Access | Times Cited: 4
Design, Synthesis, Formulation, and Bioevaluation of Trisubstituted Triazines as Highly Selective mTOR Inhibitors for the Treatment of Human Breast Cancer
Qiwen Sun, Yuxiu Chu, Nana Zhang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 7330-7358
Closed Access | Times Cited: 4
Interplay of p62-mTORC1 and EGFR signaling promotes cisplatin resistance in oral cancer
Hsiu-Chuan Chang, Cheng‐Chieh Yang, Lai‐Keng Loi, et al.
Heliyon (2024) Vol. 10, Iss. 6, pp. e28406-e28406
Open Access | Times Cited: 3
The Function and Mechanism of Long Noncoding RNAs in Adipogenic Differentiation
Junhao Chen, Yi Pan, Yunhui Lu, et al.
Genes (2024) Vol. 15, Iss. 7, pp. 875-875
Open Access | Times Cited: 3
Developing new PI3Kγ inhibitors by combining pharmacophore modeling, molecular dynamic simulation, molecular docking, fragment-based drug design, and virtual screening
Jingyu Zhu, Dan Sun, Xintong Li, et al.
Computational Biology and Chemistry (2023) Vol. 104, pp. 107879-107879
Closed Access | Times Cited: 9
Recent green chemistry approaches for pyrimidine derivatives as a potential anti-cancer agent: An overview (2013–2023)
Kumari Kajal, Ruchi Shakya, Mohd Rashid, et al.
Sustainable Chemistry and Pharmacy (2023) Vol. 37, pp. 101374-101374
Closed Access | Times Cited: 9
Discovery of (S)-N1-(thiazol-2-yl) pyrrolidine-1,2-dicarboxamide derivatives targeting PI3Ka/HDAC6 for the treatment of cancer
Yanfei Zhang, Jin‐Lai Gao, Jiming Wu, et al.
Bioorganic & Medicinal Chemistry Letters (2023) Vol. 94, pp. 129462-129462
Closed Access | Times Cited: 8
Dual inhibition of glycolysis and glutaminolysis for synergistic therapy of rheumatoid arthritis
Shanzay Ahmed, Christopher B. Mahony, Alyssa Torres, et al.
Arthritis Research & Therapy (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 8
ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines
Chung‐Pu Wu, Cheng‐Yu Hung, Ya‐Ju Hsieh, et al.
Cells (2023) Vol. 12, Iss. 7, pp. 1056-1056
Open Access | Times Cited: 7
Visualization of the relationship between fungi and cancer from the perspective of bibliometric analysis
Jiawei Xu, Ying Zeng, C. X. Yu, et al.
Heliyon (2023) Vol. 9, Iss. 8, pp. e18592-e18592
Open Access | Times Cited: 7
Influence of Extracellular Vesicles on Lung Stromal Cells during Breast Cancer Metastasis
Urvi Patel, David Susman, Alison L. Allan
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11801-11801
Open Access | Times Cited: 7
Synthesis, structure characterization, DFT calculations, and computational anticancer activity investigations of 1-phenyl ethanol derivatives
Ahmed M. Senan, Muhammed Tılahun Muhammed, Laila A. Al‐Shuraym, et al.
Journal of Molecular Structure (2023) Vol. 1294, pp. 136323-136323
Closed Access | Times Cited: 6
Protein intake in cancer: Does it improve nutritional status and/or modify tumour response to chemotherapy?
Martin Boutière, Cécile Cottet‐Rousselle, Céline Coppard, et al.
Journal of Cachexia Sarcopenia and Muscle (2023) Vol. 14, Iss. 5, pp. 2003-2015
Open Access | Times Cited: 6
Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects
Jiarui Hu, Siyu Fu, Zixuan Zhan, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116109-116109
Closed Access | Times Cited: 6
Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma
Helena Codina‐Martínez, Sara Lucila Lorenzo‐Guerra, Virginia N. Cabal, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15110-15110
Open Access | Times Cited: 5
Is it still worth renewing nucleoside anticancer drugs nowadays?
Zai‐Qun Liu
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115987-115987
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top